Kailera Therapeutics Welcomes New CFO Laurie Stelzer
Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for obesity and related conditions, has made an important leadership addition. The company recently announced the appointment of Laurie Stelzer as its Chief Financial Officer (CFO). In this role, she will lead Kailera's financial organization, focusing on financial operations, investor relations, information technology, and managing company facilities.
Laurie Stelzer's Expertise and Role
Laurie Stelzer is no stranger to high-stakes financial environments. With a career spanning over 25 years in the biopharmaceutical industry, Laurie brings a wealth of experience leading finance functions for high-growth companies. Ron Renaud, the President and CEO of Kailera, expressed excitement about Laurie joining the team, stating, "Her extensive experience will be vital as we move into our next growth phase. She has a proven track record in corporate finance and strategy, which will be crucial for our mission to innovate in obesity treatment."
Building on a Strong Foundation
Laurie shares Kailera's vision of enhancing lives through effective therapies. "I am passionate about developing impactful treatments and thrilled to collaborate with the dedicated team at Kailera," she noted. This synergy marks an optimistic step forward for the company as it strives to expand its horizons in the competitive biopharmaceutical landscape.
Previous Leadership Roles
Before joining Kailera, Laurie served as CFO of Orna Therapeutics. Her tenure there included overseeing a comprehensive range of functions such as finance, investor relations, and operations. Laurie's impressive resume also includes significant positions at ReNAgade Therapeutics, Mirati Therapeutics, and Arena Pharmaceuticals, where she played an essential role in Arena's strategic growth leading to its substantial acquisition by Pfizer. The breadth of her experience in finance and strategy throughout top companies highlights her capability to contribute meaningfully to Kailera.
About Kailera Therapeutics
Kailera Therapeutics is strategically focused on developing therapies aimed at transforming weight management. One of its standout programs is KAI-9531, an injectable GLP-1/GIP receptor dual agonist that has shown promising results in clinical trials for obesity and type 2 diabetes. The company is positioned to advance a diverse pipeline of drug candidates that leverage various mechanisms and delivery methods, underscoring its commitment to improving the health and well-being of individuals dealing with obesity.
Further Information
Kailera operates from both Waltham and San Diego, creating a strong foundation for its scientific and strategic endeavors. Interested parties can learn more about Kailera's ambitious projects and therapeutic innovations by visiting their official website or following their pages on social media platforms.
Contact Details
For any inquiries, the contact person at Kailera Therapeutics is Maura Gavaghan, the Vice President of Corporate Communications and Investor Relations. She can be reached via email for any further information or details regarding the company's future initiatives.
Frequently Asked Questions
Who is the new CFO of Kailera Therapeutics?
Laurie Stelzer has been appointed as the new Chief Financial Officer of Kailera Therapeutics.
What is Kailera Therapeutics focused on?
Kailera focuses on developing next-generation therapies for obesity and related health conditions.
What experience does Laurie Stelzer bring to Kailera?
Laurie has over 25 years of experience in biopharmaceutical finance, having held significant roles in several companies.
What are Kailera's primary products?
Kailera is developing KAI-9531, an innovative therapy being researched for obesity and type 2 diabetes.
Where is Kailera Therapeutics located?
Kailera operates from offices in Waltham, MA, and San Diego, CA.
